Figure 1:
RSPO2 rs555008 and overall survival among patients with KRAS wild-type tumors. A Training cohort: RSPO2 rs555008 and OS (FIRE-3 FOLFIRI/bevacizumab arm). B Validation cohort: RSPO2 rs555008 and OS (TRIBE FOLFIRI/bevacizumab arm). C Control cohort: RSPO2 rs555008 and OS (FIRE-3 FOLFIRI/cetuximab arm).